Mono-L-aspartyl chlorin e6

Hayashi J, Kuroiwa Y Sato H, et al. Transadventitial localization of atheromatous plaques by fluorescence emission spectrum analysis of mono-L-aspartyl chlorin e6. Cardiovasc Res 1993 27 1943-1947. 

Uchimura N, Aizawa K, Nagae 7 et al. In vivo accumulation of mono-L-aspartyl chlorin e6 in injured arteries after angioplasty. J Japan Soc Laser Surg Med 2000 21(1) 1-8. 

Nagae 7, Aizawa K, Uchimura N, et al. Endovascular photodynamic therapy using mono-L-aspartyl chlorin e6 to inhibit intimal hyperplasia in balloon-injured rabbit arteries. Lasers Surg Med 2001 28 381-388. 

Preclinical studies using another chlorin, mono-L-aspartyl chlorin e6 (NPe6) have been conducted in rabbits and monkeys (34). PDT using Npe6 was performed... 

Mori K, Yoneya S, Ohta M, et al. Angiographic and histologic effects of fundus photodynamic therapy with a hydrophilic sensitizer (mono-L-aspartyl chlorin e6). Ophthalmology 1999 106 1384-1391. 

Roberts WG, Liaw LH, Berns MW. In vitro photosensitization II. An electron microscopy study of cellular destruction with mono-L-aspartyl chlorin e6 and photofrin II. Lasers Surg Med 1989 9 102-108. 

The Ce6 is loealised in lisosomes where it induces damage after irradiation. The Ce6 derivative agents, including the mono-L-aspartyl chlorine e6 (Ace6), the diaspartyl Ce6, the monoseryl Ce6 and other derivative amino acids, which are more lipophilic, are better retained by the tumors and therefore induce a better tumor destruction than the Ce6 agent itself [41,42]. 

S.W. Taber, V.H. Fingar, C.T. Coots, T.J. Wieman (1998). Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease a Phase I clinical study. Clin. Cancer Res., 4, 2741-2746. 

Wong, T. W., Aizawa, K., Sheyhedin, 1., Wushur, C., and Kato, H. (2003). Pilot study of topical delivery of mono-L-aspartyl chlorin e6 (NPe6) implication of topical NPe6-photo-dynamic therapy, J. Pharmacol. Sci., 93 136-142. 

---